http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
HyBryte™ Expanded Treatment Results to be Presented at the European Organisation for Research and Treatment of Cancer Conference
-
Soligenix (SNGX) Announces Partnership with Sterling Pharma Solutions
-
Soligenix Announces Partnership with Sterling Pharma Solutions
-
Nova Minerals and Soligenix Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Join Soligenix's Exclusive Live Investor Webinar and Q&A Session on September 18, 2024
-
Soligenix (SNGX) Receives European Patent for Improved Production of Synthetic Hypericin
-
Soligenix Receives European Patent for Improved Production of Synthetic Hypericin
-
Soligenix and American Resources Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Soligenix Announces Recent Accomplishments And Second Quarter 2024 Financial Results
-
PRISM MarketView Features Q&A with Dr. Ellen Kim: Soligenix's HyBryte™— Lighting the Way Towards Commercial Success with Promising FLASH Study Results
-
Soligenix(SNGX): Expanded HyBryte Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
-
Expanded HyBryte™ Treatment Demonstrating Positive Outcomes in Early-Stage Cutaneous T-Cell Lymphoma
-
Soligenix (SNGX) Announces Positive Results from a Comparative Study of HyBryte Against Valchlor
-
Soligenix Announces Positive Clinical Results from a Comparative Study Evaluating HyBryte™ Against Valchlor® in the Treatment of Cutaneous T-Cell Lymphoma
-
A Comparison of Vaccine Technologies to be Presented at the ASM Microbe Conference
-
Soligenix and Sharps Technology Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Setting the Stage for Success: PRISM MarketView Highlights Soligenix's Promising HyBryte™ Replication Trial
-
Soligenix, Inc. (SNGX) Announces Reverse Stock Split
-
Soligenix Announces Reverse Stock Split
-
Soligenix Encourages Stockholders to Vote their Shares at the Annual Meeting
-
Soligenix, Inc. Announces Adjournment of Annual Meeting, Information for Reconvened Annual Meeting
-
Soligenix (SNGX) Encourages Stockholders to Vote "FOR" Reverse Stock Split
-
Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split
-
PRISM MarketView Highlights Soligenix, Inc. as it Builds on Compelling Phase 3 Data with Key Catalysts on the Horizon
-
SuVax™ and MarVax™ Thermostable Vaccine Platform to be Presented at the Vaccine Technology IX Conference
-
Soligenix Encourages Stockholders to Vote Prior to Annual Meeting
-
Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice
-
Soligenix Announces Recent Accomplishments And First Quarter 2024 Financial Results
-
Soligenix to Present at Upcoming Conferences
-
Soligenix Extends Patent Protection for its Filovirus Vaccine Platform to the United Kingdom and South Africa
-
Soligenix, Inc. (SNGX) Announces FDA Grants Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
-
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Marburg Marburgvirus Infection
-
Soligenix (SNGX) Granted FDA Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
-
FDA Grants Soligenix Orphan Drug Designation for the Prevention and Post-Exposure Prophylaxis Against Sudan Ebolavirus Infection
-
Soligenix (SNGX) Enters Agreement with EMA on Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte
-
Soligenix Announces Agreement on the Design of a Second Confirmatory Placebo-Controlled Trial for HyBryte™ With the European Medicines Agency
-
Soligenix Announces Recent Accomplishments and Year End 2023 Financial Results
-
Soligenix, Inc. (SNGX) Forms Behçet's Disease Medical Advisory Board
-
Soligenix Announces Formation of Behçet's Disease Medical Advisory Board
-
Soligenix and Mobilicom Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
-
Soligenix to Present at The Microcap Conference
-
Soligenix, Inc. (SNGX)Announces FDA Grants "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
-
FDA Grants Soligenix "Fast Track" Designation for Dusquetide in the Treatment of Oral Lesions of Behçet's Disease
-
Soligenix (SNGX) Reports Top-line Results of the Phase 2a Study of SGX302
-
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
-
Soligenix (SNGX) Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
-
Soligenix Announces Publication Demonstrating Complete Protection Against Filovirus Disease in Nonhuman Primate Models of Ebola and Marburg Viruses
-
"HyBryte™ Use in Early-Stage Cutaneous T-Cell Lymphoma" Published in Frontiers in Drug Discovery
-
Soligenix (SNGX) Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
-
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Dusquetide in the Treatment of Aphthous Ulcers in Behçet's Disease
